Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
High serum concentrations of the phosphaturic hormone, fibroblast growth factor 23 (FGF23), contribute to various tissue injuries. In chronic kidney disease, the sources of FGF23 and the stimuli that control FGF23 production differ from those in the physiologic scenario. Mediators of inflammation are intensively studied as potential factors that contribute to FGF23 elevations and thereby might function as drug targets to lower FGF23 levels. The present study focuses on tumor necrosis factor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.kint.2019.05.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of Cardiovascular Risks by CT-Derived Calcium Scoring and FGF-23 in Patients with Renal Hyperparathyroidism Undergoing Near-Total Parathyroidectomy and Cinacalcet Therapy: A Prospective Pilot Study.
Indian J Endocrinol Metab
August 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Introduction: Near-total parathyroidectomy (NPTX) could provide persistent improvements in dysregulated mineral metabolism, leading to a reduction in all-cause and cardiovascular (CV) mortality by reducing coronary artery calcium score (CACS) in refractory secondary hyperparathyroidism (SHPT). In this study, we have attempted to compare the effect of NPTX and cinacalcet therapy in patients with refractory SHPT on dialysis, with regard to their effects on CACS and FGF-23.
Methods: A total of 14 patients with refractory SHPT were followed prospectively.
Clinical Profile and Treatment Outcomes of Tumour-Induced Osteomalacia - A Single-Centre Experience.
Indian J Endocrinol Metab
August 2025
Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Introduction: Tumour-induced osteomalacia (TIO) is rare. At our referral centre, we see a substantial number of TIO. Therefore, we planned to study their profile and treatment outcomes to provide insight in management.
View Article and Find Full Text PDFRAASi, MRA and FGF-23 in CKD progression: the usual suspects?
Minerva Urol Nephrol
September 2025
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy -
Chronic kidney disease (CKD) affects almost 10% of the global population and is a significant health issue. The presence of CKD increases the risk of fatal and non-fatal cardiovascular events, overall mortality, and progression of renal damage leading to kidney failure. Inhibiting the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme inhibitor or angiotensin II receptor blockers reduces proteinuria and slows eGFR decline in CKD patients.
View Article and Find Full Text PDFElevated serum levels of monocyte chemoattractant protein-1 in 71 patients 3 months after elective cardiac surgery suggest a potential link to persistent inflammation but not an increased propensity for perioperative cerebrovascular events.
Front Med (Lausanne)
August 2025
Department of Anesthesiology and Perioperative Care, Mayo Clinic, Rochester, MN, United States.
Background: Monocyte chemoattractant protein 1 (MCP-1) plays a critical role in the transmigration of peripheral monocytes, a central mechanism underlying chronic inflammation. In this study, we investigate postoperative serum kinetics of MCP-1 as a potential contributor to postoperative neurocognitive decline, arteriosclerosis, and the development of organ failures.
Methods: Seventy-one patients undergoing elective cardiac surgery were included in this study.
Early-stage therapeutic efficacy of TNAP inhibition using a novel milder murine model of CKD-MBD.
Exp Anim
September 2025
Daiichi Sankyo Co., Ltd.
Chronic kidney disease (CKD) is a complicated systemic disease displaying various pathophysiological symptoms including mineral bone disorder (CKD-MBD). Ideally, early intervention for CKD-MBD would be desirable, however, there is not enough evidence regarding treatment of CKD-MBD, especially in its early stages, due to its multifactorial pathophysiology and the difficulty in generating adequate animal models. In this study, we evaluated the efficacy of a tissue nonspecific alkaline phosphatase (TNAP) inhibitor, SBI-425 in a CKD-MBD animal model, produced by a combination of nephrectomy and high inorganic phosphate (P) diet.
View Article and Find Full Text PDF